Roche Bets Big on Brain Health in Aging China

As China addresses its aging population, Roche is deepening its investment in the country's neuroscience sector. This strategic expansion encompasses drug development, advanced diagnostics, manufacturing, and digital health solutions aimed at neurological disorders. The World Health Organization forecasts that neurodegenerative diseases could soon become the world's second-leading cause of death.

China has seen nearly 17 million people living with Alzheimer's and over 5 million with Parkinson's as of 2021. In response, the nation launched a comprehensive action plan by 2030 to bolster dementia prevention, screening, and care services.

Roche's commitment to neuroscience spans nearly a century, with its neuroscience business generating 9.8 billion Swiss francs in revenue last year. An experimental drug, Trontinemab, is utilizing Roche's Brainshuttle technology to enhance drug delivery across the blood-brain barrier, showing promise in plaque removal with fewer side effects.

Beyond therapies, Roche is investing in diagnostics, like new blood-based biomarkers, to enable earlier detection of neurodegenerative diseases. Experts highlight that late diagnosis remains a significant obstacle, emphasizing the goal of delaying disease onset and slowing progression to improve patients' quality of life.